{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:41:12Z","timestamp":1792226472498,"version":"4.4.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s10072-026-09485-4","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:04:58Z","timestamp":1792224298000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between IGFBP-3 and longitudinal neuropsychiatric symptom trajectories in early Parkinson\u2019s disease: a longitudinal cohort study"],"prefix":"10.1007","volume":"47","author":[{"given":"Chaofan","family":"Geng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5493-9430","authenticated-orcid":false,"given":"Chen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,17]]},"reference":[{"key":"9485_CR1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/bs.irn.2023.11.001","volume":"174","author":"L Batzu","year":"2024","unstructured":"Batzu L, Podlewska A, Gibson L, Chaudhuri KR, Aarsland D (2024) A general clinical overview of the non-motor symptoms in Parkinson\u2019s disease: Neuropsychiatric symptoms. Int Rev Neurobiol 174:59\u201397. https:\/\/doi.org\/10.1016\/bs.irn.2023.11.001","journal-title":"Int Rev Neurobiol"},{"issue":"8","key":"9485_CR2","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1002\/mds.26643","volume":"31","author":"MPG Broen","year":"2016","unstructured":"Broen MPG, Narayen NE, Kuijf ML, Dissanayaka NNW, Leentjens AFG (2016) Prevalence of anxiety in Parkinson\u2019s disease: A systematic review and meta-analysis. Mov Disord 31(8):1125\u20131133. https:\/\/doi.org\/10.1002\/mds.26643","journal-title":"Mov Disord"},{"key":"9485_CR3","doi-asserted-by":"publisher","first-page":"104749","DOI":"10.1016\/j.neubiorev.2022.104749","volume":"141","author":"S Cong","year":"2022","unstructured":"Cong S, Xiang C, Zhang S, Zhang T, Wang H, Cong S (2022) Prevalence and clinical aspects of depression in Parkinson\u2019s disease: A systematic review and meta-analysis of 129 studies. Neurosci Biobehav Rev 141:104749. https:\/\/doi.org\/10.1016\/j.neubiorev.2022.104749","journal-title":"Neurosci Biobehav Rev"},{"issue":"2","key":"9485_CR4","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/mds.25664","volume":"29","author":"GW Duncan","year":"2014","unstructured":"Duncan GW, Khoo TK, Yarnall AJ, O\u2019Brien JT, Coleman SY, Brooks DJ et al (2014) Health-related quality of life in early Parkinson\u2019s disease: The impact of nonmotor symptoms. Mov Disord 29(2):195\u2013202. https:\/\/doi.org\/10.1002\/mds.25664","journal-title":"Mov Disord"},{"issue":"3","key":"9485_CR5","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1017\/S0033291715002196","volume":"46","author":"S Landau","year":"2016","unstructured":"Landau S, Harris V, Burn DJ, Hindle JV, Hurt CS, Samuel M et al (2016) Anxiety and anxious-depression in Parkinson\u2019s disease over a 4-year period: A latent transition analysis. Psychol Med 46(3):657\u2013667. https:\/\/doi.org\/10.1017\/S0033291715002196","journal-title":"Psychol Med"},{"key":"9485_CR6","doi-asserted-by":"publisher","first-page":"104896","DOI":"10.1016\/j.neubiorev.2022.104896","volume":"142","author":"S Bhalla","year":"2022","unstructured":"Bhalla S, Mehan S, Khan A, Rehman MU (2022) Protective role of IGF-1 and GLP-1 signaling activation in neurological dysfunctions. Neurosci Biobehav Rev 142:104896. https:\/\/doi.org\/10.1016\/j.neubiorev.2022.104896","journal-title":"Neurosci Biobehav Rev"},{"key":"9485_CR7","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s10072-022-06490-1","volume":"44","author":"X Shi","year":"2023","unstructured":"Shi X, Zheng J, Ma J, Li D, Gu Q, Chen S et al (2023) Correlation between serum IGF-1 and EGF levels and neuropsychiatric and cognitive in Parkinson\u2019s disease patients. Neurol Sci 44:881\u2013887. https:\/\/doi.org\/10.1007\/s10072-022-06490-1","journal-title":"Neurol Sci"},{"key":"9485_CR8","doi-asserted-by":"publisher","first-page":"111683","DOI":"10.1016\/j.pnpbp.2026.111683","volume":"146","author":"S Chen","year":"2026","unstructured":"Chen S, Niu YX, Li CH, Xiang XF, Shao JY, Yang HQ et al (2026) Serum IGF-1 and anxiety trajectories in Parkinson\u2019s disease. Prog Neuropsychopharmacol Biol Psychiatry 146:111683. https:\/\/doi.org\/10.1016\/j.pnpbp.2026.111683","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"9485_CR9","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3389\/fcell.2020.00286","volume":"8","author":"SV Shrivastav","year":"2020","unstructured":"Shrivastav SV, Bhardwaj A, Pathak KA, Shrivastav A (2020) Insulin-like growth factor binding protein-3 (IGFBP-3): Unraveling the role in mediating IGF-independent effects within the cell. Front Cell Dev Biol 8:286. https:\/\/doi.org\/10.3389\/fcell.2020.00286","journal-title":"Front Cell Dev Biol"},{"key":"9485_CR10","doi-asserted-by":"publisher","first-page":"132464","DOI":"10.1155\/2009\/132464","volume":"2009","author":"D Tuncel","year":"2009","unstructured":"Tuncel D, Tolun FI, Toru I (2009) Serum insulin-like growth factor-1 and nitric oxide levels in Parkinson\u2019s disease. Parkinsons Dis 2009:132464. https:\/\/doi.org\/10.1155\/2009\/132464","journal-title":"Parkinsons Dis"},{"key":"9485_CR11","doi-asserted-by":"publisher","first-page":"1682274","DOI":"10.3389\/fnins.2025.1682274","volume":"19","author":"L Han","year":"2025","unstructured":"Han L, Liu Y, Tan C, Mo L, Su H, Ma P et al (2025) Revealing cerebrospinal fluid biomarkers in Parkinson\u2019s disease dementia based on iTRAQ proteomics research. Front Neurosci 19:1682274. https:\/\/doi.org\/10.3389\/fnins.2025.1682274","journal-title":"Front Neurosci"},{"issue":"12","key":"9485_CR12","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W et al (2015) MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord 30(12):1591\u20131601. https:\/\/doi.org\/10.1002\/mds.26424","journal-title":"Mov Disord"},{"key":"9485_CR13","volume-title":"Manual for the State-Trait Anxiety Inventory (Form Y)","author":"CD Spielberger","year":"1983","unstructured":"Spielberger CD, Gorsuch RL, Lushene R, Vagg PR, Jacobs GA (1983) Manual for the State-Trait Anxiety Inventory (Form Y). Consulting Psychologists, Palo Alto, CA"},{"issue":"1\u20132","key":"9485_CR14","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1300\/J018v05n01_09","volume":"5","author":"JI Sheikh","year":"1986","unstructured":"Sheikh JI, Yesavage JA (1986) Geriatric Depression Scale (GDS): Recent evidence and development of a shorter version. Clin Gerontol 5(1\u20132):165\u2013173. https:\/\/doi.org\/10.1300\/J018v05n01_09","journal-title":"Clin Gerontol"},{"issue":"15","key":"9485_CR15","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P et al (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Mov Disord 23(15):2129\u20132170. https:\/\/doi.org\/10.1002\/mds.22340","journal-title":"Mov Disord"},{"issue":"19","key":"9485_CR16","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","volume":"385","author":"LA Inker","year":"2021","unstructured":"Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y et al (2021) New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med 385(19):1737\u20131749. https:\/\/doi.org\/10.1056\/NEJMoa2102953","journal-title":"N Engl J Med"},{"issue":"15","key":"9485_CR17","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/mds.23429","volume":"25","author":"CL Tomlinson","year":"2010","unstructured":"Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease. Mov Disord 25(15):2649\u20132653. https:\/\/doi.org\/10.1002\/mds.23429","journal-title":"Mov Disord"},{"issue":"1","key":"9485_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v067.i01","volume":"67","author":"D Bates","year":"2015","unstructured":"Bates D, M\u00e4chler M, Bolker B, Walker S (2015) Fitting linear mixed-effects models using lme4. J Stat Softw 67(1):1\u201348. https:\/\/doi.org\/10.18637\/jss.v067.i01","journal-title":"J Stat Softw"},{"key":"9485_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-19425-7","volume-title":"Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis","author":"FE Harrell Jr","year":"2015","unstructured":"Harrell FE Jr (2015) Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis, 2nd edn. Springer, Cham. https:\/\/doi.org\/10.1007\/978-3-319-19425-7","edition":"2"},{"issue":"3","key":"9485_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i03","volume":"45","author":"S van Buuren","year":"2011","unstructured":"van Buuren S, Groothuis-Oudshoorn K (2011) mice: Multivariate imputation by chained equations in R. J Stat Softw 45(3):1\u201367. https:\/\/doi.org\/10.18637\/jss.v045.i03","journal-title":"J Stat Softw"},{"issue":"429","key":"9485_CR21","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1080\/01621459.1995.10476493","volume":"90","author":"JM Robins","year":"1995","unstructured":"Robins JM, Rotnitzky A, Zhao LP (1995) Analysis of semiparametric regression models for repeated outcomes in the presence of missing data. J Am Stat Assoc 90(429):106\u2013121. https:\/\/doi.org\/10.1080\/01621459.1995.10476493","journal-title":"J Am Stat Assoc"},{"key":"9485_CR22","doi-asserted-by":"publisher","first-page":"107551","DOI":"10.1016\/j.psyneuen.2025.107551","volume":"180","author":"XF Xiang","year":"2025","unstructured":"Xiang XF, Li CH, Shao JY, Li R, Zhang HJ, Zhang JW, Chen S (2025) Longitudinal association between plasma epidermal growth factor and the progression of anxiety and depressive symptoms in Parkinson\u2019s disease. Psychoneuroendocrinology 180:107551. https:\/\/doi.org\/10.1016\/j.psyneuen.2025.107551","journal-title":"Psychoneuroendocrinology"},{"key":"9485_CR23","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/bs.irn.2017.05.024","volume":"133","author":"A Schrag","year":"2017","unstructured":"Schrag A, Taddei RN (2017) Depression and anxiety in Parkinson\u2019s disease. Int Rev Neurobiol 133:623\u2013655. https:\/\/doi.org\/10.1016\/bs.irn.2017.05.024","journal-title":"Int Rev Neurobiol"},{"issue":"1","key":"9485_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.6065\/apem.2013.18.1.9","volume":"18","author":"HS Kim","year":"2013","unstructured":"Kim HS (2013) Role of insulin-like growth factor binding protein-3 in glucose and lipid metabolism. Ann Pediatr Endocrinol Metab 18(1):9\u201312. https:\/\/doi.org\/10.6065\/apem.2013.18.1.9","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"9485_CR25","doi-asserted-by":"publisher","first-page":"101245","DOI":"10.1016\/j.molmet.2021.101245","volume":"52","author":"D LeRoith","year":"2021","unstructured":"LeRoith D, Holly JMP, Forbes BE (2021) Insulin-like growth factors: Ligands, binding proteins, and receptors. Mol Metab 52:101245. https:\/\/doi.org\/10.1016\/j.molmet.2021.101245","journal-title":"Mol Metab"},{"issue":"5","key":"9485_CR26","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1210\/endrev\/bnad008","volume":"44","author":"RC Baxter","year":"2023","unstructured":"Baxter RC (2023) Signaling pathways of the insulin-like growth factor binding proteins. Endocr Rev 44(5):753\u2013778. https:\/\/doi.org\/10.1210\/endrev\/bnad008","journal-title":"Endocr Rev"},{"issue":"6","key":"9485_CR27","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1210\/er.2001-0033","volume":"23","author":"SM Firth","year":"2002","unstructured":"Firth SM, Baxter RC (2002) Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23(6):824\u2013854. https:\/\/doi.org\/10.1210\/er.2001-0033","journal-title":"Endocr Rev"},{"issue":"5","key":"9485_CR28","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1210\/er.2008-0028","volume":"30","author":"S Jogie-Brahim","year":"2009","unstructured":"Jogie-Brahim S, Feldman D, Oh Y (2009) Unraveling insulin-like growth factor binding protein-3 actions in human disease. Endocr Rev 30(5):417\u2013437. https:\/\/doi.org\/10.1210\/er.2008-0028","journal-title":"Endocr Rev"},{"issue":"5","key":"9485_CR29","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1210\/en.2006-0195","volume":"147","author":"P Cohen","year":"2006","unstructured":"Cohen P (2006) Insulin-like growth factor binding protein-3: insulin-like growth factor independence comes of age. Endocrinology 147(5):2109\u20132111. https:\/\/doi.org\/10.1210\/en.2006-0195","journal-title":"Endocrinology"},{"issue":"6","key":"9485_CR30","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1093\/brain\/awh445","volume":"128","author":"P Remy","year":"2005","unstructured":"Remy P, Doder M, Lees A, Turjanski N, Brooks D (2005) Depression in Parkinson\u2019s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 128(6):1314\u20131322. https:\/\/doi.org\/10.1093\/brain\/awh445","journal-title":"Brain"},{"issue":"1","key":"9485_CR31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrneurol.2011.189","volume":"8","author":"D Aarsland","year":"2012","unstructured":"Aarsland D, P\u00e5hlhagen S, Ballard CG, Ehrt U, Svenningsson P (2012) Depression in Parkinson disease\u2014epidemiology, mechanisms and management. Nat Rev Neurol 8(1):35\u201347. https:\/\/doi.org\/10.1038\/nrneurol.2011.189","journal-title":"Nat Rev Neurol"},{"key":"9485_CR32","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1038\/s41380-023-02136-6","volume":"28","author":"A Nu\u00f1ez","year":"2023","unstructured":"Nu\u00f1ez A, Zegarra-Valdivia J, Fernandez de Sevilla D, Pignatelli J, Torres Aleman I (2023) The neurobiology of insulin-like growth factor I: from neuroprotection to modulation of brain states. Mol Psychiatry 28:3220\u20133230. https:\/\/doi.org\/10.1038\/s41380-023-02136-6","journal-title":"Mol Psychiatry"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09485-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-09485-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09485-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:04:59Z","timestamp":1792224299000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-09485-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,17]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["9485"],"URL":"https:\/\/doi.org\/10.1007\/s10072-026-09485-4","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,17]]},"assertion":[{"value":"25 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of Henan Provincial People\u2019s Hospital, Zhengzhou, China. Written informed consent was obtained from all participants or their legally authorized representatives prior to participation.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Clinical trial registration","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"861"}}